Login to Your Account



Post-ASCO, Opinions Mixed On Kidney Cancer Drug Race

By Randall Osborne


Monday, May 23, 2005
Late last year, when Onyx Pharmaceuticals Inc. and partner Bayer Pharmaceuticals Corp. disclosed their plan to hold off seeking approval of their kidney cancer drug sorafenib (previously BAY 43-9006) until they had Phase III data in hand, Wall Street blanched. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription